仁度生物2025年预计扭亏为盈，扣非净利润仍为亏损

Core Viewpoint - RenDu Bio (688193) is expected to turn a profit in 2025, with a projected net profit attributable to shareholders ranging from 7.2 million to 10.8 million yuan, despite a net loss when excluding non-recurring gains and losses [1] Group 1: Financial Performance - The company anticipates a net profit of 7.2 million to 10.8 million yuan for 2025, indicating a turnaround from previous losses [1] - The net profit excluding non-recurring gains and losses is projected to be a loss of 11 million to 14.5 million yuan [1] - The performance change is primarily attributed to cost reduction and efficiency improvements, as well as the recovery of some receivables [1] Group 2: Related Party Transactions - On January 15, 2026, the company held a board meeting to review the 2026 annual routine related party transaction proposal, which may require further monitoring [2]